Physician profile
Aasim Mohammed
NPI 1326477233
$3,742.31
in general payments reported to CMS, 2019-2025
15 companies · $789 in 2025
The $789 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $165 · 2021: $763 · 2022: $868 · 2023: $684 · 2024: $473 · 2025: $789.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,946.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,946.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,090.40 | 2021-2025 | Breztri, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $988.55 | 2020-2025 | Nucala, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $474.08 | 2021-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Genzyme Corporation | $258.92 | 2022-2024 | |
| Pulmonx Corporation | $237.38 | 2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| United Therapeutics Corporation | $143.37 | 2022-2025 | Tyvaso, Tyvaso |
| Insmed, INC. | $141.24 | 2020-2023 | Arikayce |
| Regeneron Healthcare Solutions, INC. | $122.15 | 2024 | Dupixent |
| Galvanize Therapeutics, INC | $103.35 | 2025 | Aliya System |
| Verona Pharma, INC. | $82.76 | 2025 | Ohtuvayre |
| Covis Pharma Gmbh | $24.15 | 2022 | |
| Amgen INC. | $21.07 | 2025 | Tezspire |
| Teva Pharmaceuticals USA, INC. | $18.78 | 2022 | |
| Novo Nordisk INC | $18.08 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $18.03 | 2023 | Uptravi, Opsumit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aasim Mohammed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.